Anidulafungin: A new echinocandin with a novel profile

Clinical Therapeutics

Volumn 27, Issue 6, 2005, Pages 657-673

  Vazquez, José A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

Anidulafungin; Antifungal; Aspergillosis; Candidemia; Candidiasis; Echinocandin

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; RIFAMPICIN; VORICONAZOLE;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DIZZINESS; DRUG ACTIVITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ESOPHAGUS DISEASE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; KIDNEY FAILURE; LEUKOPENIA; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PHARMACODYNAMICS; PHLEBITIS; RASH; REVIEW; SIDE EFFECT; THROMBOPHLEBITIS; TREATMENT OUTCOME; VOMITING;

EID: 27744463412     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.06.010     Document Type: Review

References (80)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-647.
2. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis. 2002;44:169-174.
3. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials. 2000;1:47-59.
4. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol. 1992;73:171-180.
5. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
6. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998; 26:781-803.
7. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
8. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant. 2004;10:73-90.
9. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42:1519-1527.
10. Trick WE, Fridkin SK, Edwards JR, et al, for the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:627-630.
11. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect. 2001;7(Suppl 2):1-7.
12. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Anti-microb Agents Chemother. 2003;47: 3149-3154.
13. Rex JH, Walsh TJ, Sobel JD, et al, for the Infectious Diseases Society of America. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30:662-678.
14. Pappas PG, Rex JH, Lee J, et al, for the NIAID Mycoses Study Group. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643.
15. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686-693.
16. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29: 1402-1407.
17. Fromtling RA. Human mycoses and advances in antifungal therapy. Drug News Perspect. 2001;14:181-192.
18. Ally R, Schurmann D, Kreisel W, et al, for the Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447-1454.
19. Barbaro G, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology. 1996;111:1169-1177.
20. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-1151.
21. Morrison VA. The role of caspofungin and the echinocandins in the antifungal armamentarium. Curr Opin Invest Drugs. 2002;3:1432-1436.
22. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis. 2003;16:533-537.
23. Chavez M, Bernal S, Valverde A, et al. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother. 1999;44:697-700.
24. Ernst ME, Klepser ME, Wolfe EJ, Pfaller MA. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp. Diagn Microbiol Infect Dis. 1996; 26:125-131.
25. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000;44:1108-1111.
26. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950-2956.
27. Johnson EM, Goldstein BP, Davey KG, Fraser MA. Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole and voriconazole against a panel of 780 yeasts obtained from five European centres. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Poster 513.
28. Uzun O, Kocagoz S, Cetinkaya Y, et al. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother. 1997;41:1156-1157.
29. Zhanel GG, Karlowsky JA, Zelenitsky SA, et al. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Antimicrob Agents Chemother. 1998;42:2446-2448.
30. Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semi-synthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997;41:863-865.
31. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis. 1998;32: 33-37.
32. Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother. 1997;41:763-766.
33. Cuenca-Estrella M, Mellado E, Diaz-Guerra TM, et al. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother. 2000;46:475-477.
34. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect. 2001;7: 11-16.
35. Serrano Mdel C, Valverde-Conde A, Chávez MM, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis. 2003;45:131-135.
36. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 1998;42:2898-2905.
37. Ostrosky-Zeichner L, Matar M, Paetznich VL, Rodriguez JR. In-vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. Monograph M-1816.
38. Philip A, Odabasi Z, Rodrigues JR, et al. In vitro synergy testing of anidulafungin (ANID) with itraconazole (ITR) and voriconazole (VOR) against Aspergillus spp. and Fusarium spp. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Monograph M-988.
39. Odabasi Z, Paetznick VL, Rodriguez JR, et al. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother. 2004;48:1912-1915.
40. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49:767-769.
41. Petraitis V, Petraitiene R, Groll AH, et al. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2001;45:471-479.
42. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother. 2001;45:2845-2855.
43. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother. 1999;43:2148-2155.
44. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 2000;44:3381-3388.
45. Dowell JA, Pu F, Lee J, et al. A clinical mass balance study of anidulafungin (ANID) showing complete fecal elimination. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Abstract A-1576.
46. Krause DS, Reinhardt J, Vazquez JA, et al, for the Anidulafungin Invasive Candidiasis Study Group. A phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021-2024.
47. Dowell JA, Stogniew M, Krause D, Henkel T. Anidulafungin pharmacokinetic/pharmacodynamic correlation: Treatment of EC. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Abstract A-1578.
48. Hoban D, Balko T, Saunders D, et al. Influence of human serum on Candida spp. Susceptibility to LY-303366. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. J-9.
49. Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. In: Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13, 2003; Glasgow, UK. Poster P-1223.
50. Dowell J, Stogniew M, Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases; May 10-13, 2003; Glasgow, UK. Poster P-1222.
51. Krause D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: Pharmacokinetics in subjects with severe hepatic impairment. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. Abstract A-1392.
52. Krause D, Marbury T, Kilfoil T, et al. Anidulafungin: Pharmacokinetics in subjects with renal impairment. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. Abstract A-1391.
53. Krause D, Marbury T, Kilfoil T, et al. Anidulafungin: Pharmacokinetics in subjects receiving hemodialysis. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, Calif. Abstract A-1390.
54. Dowell JA, Knebel W, Ludden T, et al. A population pharmacokinetic analysis of anidulafungin. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Abstract A-1575.
55. Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590-598.
56. Stogniew M, Dowell J, Krause D, Henkel TJ. Population pharmacokinetics confirms absence of anidulafungin drug-drug interactions. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Poster 1035.
57. Dowell J, Schranz J, Stogniew M, et al. Assessment of the pharmacokinetics of anidulafungin in patients with invasive aspergillosis receiving concomitant liposomal amphotericin. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Poster 1036.
58. Stone JA, Li S, Winchell G, et al. Population pharmacokinetics of caspofungin in candidiasis patients. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Abstract A-1571.
59. Stone JA, Migoya E, Hickey L, et al. Drug interactions between caspofungin and nelfinavir or rifampin. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Abstract A-1605.
60. Dowell J, Schranz J, Wilson J, et al. Anidulafungin (ANID) pharmacokinetics are not affected by concomitant voriconazole (VORI). In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Poster P-1034.
61. Schranz J, Dowell J, Krause D, Henkel T. Anidulafungin and cyclosporine: Safe coadministration without dosing adjustment. In: Program and abstracts of the 15th Congress of the International Society for Human and Animal Mycology; May 25-29, 2003; San Antonio, Tex. Abstract.
62. Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005;45:227-233.
63. Cancidas (caspofungin) 70 mg [product information]. Haarlem, Netherlands: Merck, Sharp, & Dohme Ltd, 2003.
64. Herbrecht R, Graham D, Schuster M, et al. Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA). In: Program and abstracts of the 2004 Tandem Bone Marrow Transplantation Meetings; March 24-26, 2004; Orlando, Fla. Abstract.
65. Benjamin DK, Driscoll T, Siebel NL, et al. Safety and pharmacokinetics of anidulafungin in pediatric patients with neutropenia. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Poster P-869.
66. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39: 770-775.
67. Vasquez J, Schranz J, Reboli A, et al. Efficacy results from a phase 2/3, open-label study of anidulafungin (ANID) in patients with fluconazole- refractory mucosal candidiasis (FRMC). In: Programs and abstracts of the Confederation of Medical Mycology (ECCM) and 7th Trends in Invasive Fungal Infections. September 28-October 1, 2003; Amsterdam, Netherlands. Poster P-044.
68. Viljoen J, Schranz JA, Krause D, et al. Clinical efficacy results from a phase 3 study of anidulafungin (ANID) versus fluconazole (FLU) in HIV negative patients with esophageal candidiasis (EC). In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Poster P1558.
69. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33: 1529-1535.
70. Vazquez J, Schranz JA, Krause D, et al. Efficacy from a phase 2/3 study of anidulafungin (ANID) in patients (pts) with azole-refractory mucosal candidiasis (ARMC). In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Poster P-1040.
71. Schranz JA, Krause D, Goldstein BP, Henkel T. Efficacy of anidulafungin (ANID) for the treatment of candidemia. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Monograph M-971.
72. Schranz J, Krause D, Henkel T. Lack of infusion-related adverse events with anidulafungin. In: Program and abstracts of the 15th Congress of the International Society for Human and Animal Mycology; May 25-29, 2003; San Antonio, Tex. Abstract 399.4.
73. Thye D, Shepherd B, White RJ, et al. Anidulafungin: A phase 1 study to identify the maximum tolerated dose in healthy volunteers. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Abstract A-36.
74. Krause D, Schranz J, Birmingham W. Safety results from a phase 3, randomized, double-blind, double-dummy study of anidulafungin (ANID) vs. fluconazole (FLU) in patients with esophageal candidiasis (EC). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Poster 136.
75. Krause D, Schranz J, Birmingham W. Lack of hepatic effect of anidulafungin. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Poster 1789.
76. Krause DS, Henkel T, Goldstein BP, Walsh TJ. Anidulafungin (ANID) vs. fluconazole (FLU) in esophageal candidiasis (EC): A phase 3, randomized, double-blind, multicenter trial. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Monograph M-1760.
77. Vicuron Pharmaceuticals announces phase 3 trial results demonstrate superiority of anidulafungin versus fluconazole in invasive candidiasis/ candidemia [Vicuron Web site]. [Date of press release.] Available at: www.vicuron.com. Accessed June 7, 2005.
78. Walsh T, Herbrecht R, Graham D, et al. Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA). In: Programs and abstracts of the 14th Focus on Fungal Infections; April 13-16, 2004; New Orleans, La. Abstract 11.
79. Pappas PG, Rex JH, Sobel JD, et al, for the Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004; 38:161-189.
80. Vazquez JA, Arganoza MT, Boikov D, et al. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. J Clin Microbiol. 1998;36:2690-2695.